Vorinostat is a drug that has received approval by the U.S. Food and Drug Administration under the brand name Zolinza for the treatment of a certain type of cancer. Vorinostat is also being studied as an investigational drug as part of a strategy to cure HIV infection. As an investigational HIV drug, vorinostat belongs to a group of drugs called latency-reversing agents. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Zolinza and Suberoylanilide hydroxamic acid. Its PubChem CID is 5311.
Vorinostat
| CAS No | 149647-78-9 |
|---|---|
| Molecular Formula | C14H20N2O3 |
| Molecular Weight | 264.32 g/mol |
| Synonyms | N'-hydroxy-N-phenyloctanediamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
S. Food and Drug Administration under the brand name Zolinza for the treatment of a certain type of cancer. Vorinostat is also being studied as an investigational drug as part of a strategy to cure HIV infection.
The listed CAS number is 149647-78-9.
The listed molecular formula is C14H20N2O3.
The listed molecular weight is 264.32 g/mol.
N'-hydroxy-N-phenyloctanediamide.
The source lists Zolinza and Suberoylanilide hydroxamic acid.